Evidence map›Paper›PMID 39747534›Full record

Observational studyScientific reports2025

Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients.

Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Immune Checkpoint Inhibitor-Related Hypophysitis: A Call for Vigilance.Endocrinology and metabolism (Seoul, Korea) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuichiro IwamotoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan. iwamoto.g@med.kawasaki-m.ac.jp.
Tomohiko KimuraDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Kazunori DanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Hideyuki IwamotoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Junpei SanadaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Yoshiro FushimiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Yukino KatakuraDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Masashi ShimodaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Shuhei NakanishiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Tomoatsu MuneDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Kohei KakuDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Hideaki KanetoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to analyze the efficacy of treatment and survival after administration of immune checkpoint inhibitor (ICI) in Japanese patients and had endocrine-related and/or other immune-related adverse events (irAEs), as well as irAEs in multiple organs. This is a single-center, retrospective, observational study of 571 Japanese patients treated with ICI at our hospital. We evaluated the occurrence of Grade 3 or higher irAEs and the life expectancy and treatment efficacy after ICI administration. Endocrine-related irAE (E-irAE), other irAE (O-irAE), endocrine-related and other irAE (EO-irAE), and multiple endocrine-related irAE (ME-irAE) were evaluated in groups. 80.8% of patients had an irAE, with the highest incidence of irAE with ipilimumab plus PD-1 inhibitor, followed by atezolizumab 59.0%, pembrolizumab 53.7%, avelumab 50.0%, and nivolumab 47.3%, Durvamumab 26.7% followed; Kaplan-Meier survival curves showed higher survival rates in patients with irAE compared to non-irAE, and higher survival rates in EO-irAE and ME-irAE compared to E-irAE and O-irAE (p < 0.001). The COX proportional hazard ratios for overall survival were E-irAE 0.611 (0.480-0.772), O-irAE 0.758 (0.597-0.957), EO-irAE 0.622 (0.466-0.819) and ME-irAE 0.463 when non-irAE was set at 1.000 (0.257-0.775). When grade 3 or higher irAEs appeared, regardless of their type, there was a trend toward higher survival and post-treatment remission rates after ICI administration. In addition to this, patients with irAEs in multiple endocrine tissues and patients with irAEs in both endocrine and other organs had a better response to treatment after ICI administration.

Indexed as

Endocrine System DiseasesImmune Checkpoint InhibitorsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedEast Asian PeopleFemaleHumansJapanKaplan-Meier EstimateMaleMiddle AgedNeoplasmsRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorspembrolizumabEndocrine disorderImmune check point inhibitorsImmune-related adverse eventsRetrospective study

Identifiers

PMID39747534
PMCPMC11695621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.